Dr Reddy's to Enter Anti-Vertigo Market with $50.5 Million Acquisition; Share Price in Focus

Dr Reddy’s Laboratories Ltd. has announced the acquisition of the STUGERON portfolio, including Stugeron® FORTE and Stugeron PLUS, from Janssen Pharmaceutica NV (JPNV), an affiliate of Johnson & Johnson. The deal, valued at $50.5 million, covers 18 markets across APAC and EMEA regions, with India and Vietnam identified as priority markets.

Strengthening CNS and Anti-Vertigo Portfolio 

The acquisition marks a significant boost for Dr Reddy’s Central Nervous System (CNS) segment while widening its presence in the anti-vertigo market. The STUGERON portfolio is based on Cinnarizine, an antihistamine prescribed for vestibular disturbances and vertigo. 

According to IQVIA MAT July 2025, the brand enjoys strong positioning in India, ranking #1 in the Cinnarizine represented pharmaceutical market (RPM) and #2 in the anti-vertigo extended represented pharmaceutical market (eRPM).

JPNV, the selling entity, is not a related party to Dr Reddy’s, and promoters of the company have no interest in the transaction. The transition of operations will be carried out gradually to ensure smooth integration across the 18 covered markets.

Official Statement from Dr. Reddy’s

As per the exchange filing, M.V. Ramana, CEO, Branded Markets (India & Emerging Markets), Dr Reddy’s, said: “Dr. Reddy’s acquisition of the STUGERON® brand reflects a steady advancement in our efforts to expand into the anti-vertigo therapeutic segment, contributing to the continued development of our CNS portfolio. 

Backed by our strong market access, we intend to extend the reach of STUGERON® and its associated products across 18 key markets in the APAC and EMEA regions, including India and Vietnam. This strategic step is in line with our broader commitment to improving patient access and advancing toward our goal of reaching over 1.5 billion patients by 2030.”

About Dr Reddy’s

Founded in 1984 and headquartered in Hyderabad, Dr Reddy’s is a leading pharmaceutical company with a strong global footprint. Its portfolio includes active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars, and over-the-counter products. The company’s therapeutic focus spans gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Dr. Reddy’s operates in key markets including the USA, India, Russia & CIS, China, Brazil, and Europe.

Read More: Dr Reddy Q1FY26 Earnings Profit Flat at ₹1,409 Crore Despite 11% Revenue Growth!

Dr Reddy's Share Price Performance 

As of September 11, 2025, at 12:08 PM, Dr Reddy’s share price is trading at ₹1,296.50 per share, reflecting a decline of 0.59% from the previous closing price. Over the past month, the stock has gained by 6.31%.

Conclusion

This acquisition adds a trusted, globally recognised brand to Dr Reddy’s CNS portfolio and strengthens its market positioning in anti-vertigo solutions. With a focus on 18 international markets and a long-term goal of reaching 1.5 billion patients by 2030, the company continues to push forward its mission of improving patient access and creating sustainable growth worldwide.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.